Pharmaceuticals, dermo-cosmetics : our brands | Pierre Fabre
Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland | Business Wire
Pierre Fabre and Lonza Enter Manufacturing Agreement for W0180 Antibody Drug Product
PIERRE FABRE GROUP Accelerating online growth with a global e-Retail upskilling programme - Artefact